1-3 of 3
David Ritchie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1017–1030.
https://doi.org/10.1158/1078-0432.CCR-22-3094
Published: 14 March 2023
View article titled, A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <em>BRAF</em> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Open the PDF for A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in <em>BRAF</em> V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study in another window
Includes: Supplementary data
Journal Articles

Abstract 11: Progression from newly diagnosed multiple myeloma to relapsed refractory multiple myeloma is associated with significant alterations in the CD4+ Treg population phenotype

Rachel Cooke, Hang Quach, Simon Harrison, Miles Prince, Rachel Koldej, David Ritchie
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 11.
https://doi.org/10.1158/1557-3265.HEMMAL17-11
Published: 14 December 2017
View article titled, Abstract 11: Progression from newly diagnosed multiple myeloma to relapsed refractory multiple myeloma is associated with significant alterations in the CD4<sup>+</sup> Treg population phenotype
Journal Articles

Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma

Kimberley Jones, Frank Vari, Colm Keane, Pauline Crooks, Jamie P. Nourse, Louise A. Seymour, David Gottlieb, David Ritchie, Devinder Gill, Maher K. Gandhi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 731–742.
https://doi.org/10.1158/1078-0432.CCR-12-2693
Published: 31 January 2013
View article titled, Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma
Open the PDF for Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma in another window
Includes: Supplementary data